JP2005500277A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005500277A5 JP2005500277A5 JP2003501491A JP2003501491A JP2005500277A5 JP 2005500277 A5 JP2005500277 A5 JP 2005500277A5 JP 2003501491 A JP2003501491 A JP 2003501491A JP 2003501491 A JP2003501491 A JP 2003501491A JP 2005500277 A5 JP2005500277 A5 JP 2005500277A5
- Authority
- JP
- Japan
- Prior art keywords
- calcitonin
- pth
- composition
- administration
- oral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 16
- 102000055006 Calcitonin Human genes 0.000 claims 11
- 108060001064 Calcitonin Proteins 0.000 claims 11
- 229960004015 calcitonin Drugs 0.000 claims 11
- 108090000445 Parathyroid hormone Proteins 0.000 claims 9
- 238000011260 co-administration Methods 0.000 claims 6
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 claims 5
- 108010068072 salmon calcitonin Proteins 0.000 claims 5
- 230000011164 ossification Effects 0.000 claims 3
- 230000004936 stimulating effect Effects 0.000 claims 2
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 claims 1
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 102000058004 human PTH Human genes 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29516901P | 2001-06-01 | 2001-06-01 | |
| US60/295,169 | 2001-06-01 | ||
| PCT/EP2002/006017 WO2002098453A2 (en) | 2001-06-01 | 2002-05-31 | Orally administering parathyroid hormone and calcitonin |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010098631A Division JP2010189423A (ja) | 2001-06-01 | 2010-04-22 | 副甲状腺ホルモンおよびカルシトニンの経口投与 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005500277A JP2005500277A (ja) | 2005-01-06 |
| JP2005500277A5 true JP2005500277A5 (enExample) | 2005-12-22 |
| JP5073153B2 JP5073153B2 (ja) | 2012-11-14 |
Family
ID=23136525
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003501491A Expired - Fee Related JP5073153B2 (ja) | 2001-06-01 | 2002-05-31 | 副甲状腺ホルモンおよびカルシトニンの経口投与 |
| JP2010098631A Pending JP2010189423A (ja) | 2001-06-01 | 2010-04-22 | 副甲状腺ホルモンおよびカルシトニンの経口投与 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010098631A Pending JP2010189423A (ja) | 2001-06-01 | 2010-04-22 | 副甲状腺ホルモンおよびカルシトニンの経口投与 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20040186050A1 (enExample) |
| EP (1) | EP1397156B1 (enExample) |
| JP (2) | JP5073153B2 (enExample) |
| KR (3) | KR20090116836A (enExample) |
| CN (2) | CN101837120A (enExample) |
| AT (1) | ATE356631T1 (enExample) |
| AU (2) | AU2002344371B2 (enExample) |
| BR (1) | BRPI0209748B1 (enExample) |
| CA (1) | CA2446929C (enExample) |
| CO (1) | CO5540323A2 (enExample) |
| CZ (1) | CZ307145B6 (enExample) |
| DE (1) | DE60218842T2 (enExample) |
| EC (1) | ECSP034858A (enExample) |
| ES (1) | ES2282436T3 (enExample) |
| HU (1) | HU229613B1 (enExample) |
| IL (2) | IL158777A0 (enExample) |
| MX (1) | MXPA03011027A (enExample) |
| NO (1) | NO330093B1 (enExample) |
| NZ (1) | NZ529439A (enExample) |
| PL (1) | PL211976B1 (enExample) |
| PT (1) | PT1397156E (enExample) |
| RU (1) | RU2300392C2 (enExample) |
| SK (1) | SK287697B6 (enExample) |
| WO (1) | WO2002098453A2 (enExample) |
| ZA (1) | ZA200308625B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5073153B2 (ja) | 2001-06-01 | 2012-11-14 | ノバルティス アーゲー | 副甲状腺ホルモンおよびカルシトニンの経口投与 |
| DE60233803D1 (de) | 2001-08-17 | 2009-11-05 | Novartis Ag | 5-cnac zur oralen verabreichung von parathormonfragmenten |
| US20050054557A1 (en) * | 2002-05-09 | 2005-03-10 | Goldberg Michael M. | Compositions for delivering parathyroid hormone and calcitonin |
| PE20070548A1 (es) | 2005-09-19 | 2007-07-12 | Emisphere Tech Inc | Formas cristalinas de la sal de di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico |
| GB0522566D0 (en) * | 2005-11-04 | 2005-12-14 | Novartis Ag | Organic compounds |
| WO2007059470A2 (en) * | 2005-11-10 | 2007-05-24 | Board Of Control Of Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
| AU2006318815B2 (en) * | 2005-11-17 | 2010-08-19 | Novartis Ag | Pharmaceutical composition |
| US8022048B2 (en) | 2007-11-02 | 2011-09-20 | Emisphere Technologies, Inc. | Method of treating vitamin B12 deficiency |
| CN104857505A (zh) * | 2008-08-18 | 2015-08-26 | 安特拉贝欧有限公司 | 用于口服给予蛋白质的方法和组合物 |
| CN102123697B (zh) * | 2008-08-18 | 2015-06-10 | 安特拉贝欧有限公司 | 用于口服给予蛋白质的方法和组合物 |
| WO2011071480A1 (en) | 2009-12-07 | 2011-06-16 | Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
| WO2012130193A1 (en) | 2011-03-31 | 2012-10-04 | Zentiva, K.S. | Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration |
| CN104800564A (zh) * | 2015-04-02 | 2015-07-29 | 中国人民解放军济南军区总医院 | 一种治疗血虚不荣型甲状旁腺功能减退症的中药组合物 |
| KR101796604B1 (ko) * | 2016-08-30 | 2017-11-10 | 목포대학교 산학협력단 | 위장관 흡수증진제를 함유하는 부갑상선 호르몬의 경구 투여 제형 |
| WO2019098811A2 (ko) | 2017-11-20 | 2019-05-23 | 주식회사 노브메타파마 | Chp(시클로-히스프로)를 포함하는 골 손실 질환의 예방, 개선 또는 치료용 조성물 |
| KR102115353B1 (ko) * | 2019-05-17 | 2020-05-26 | 주식회사 노브메타파마 | Chp(사이클로-히스프로) 및 부갑상선 호르몬을 포함하는 골 손실 질환의 예방, 개선 또는 치료용 조성물 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4692433A (en) * | 1983-10-12 | 1987-09-08 | The Regents Of The University Of California | Method and composition for regulating serum calcium levels of mammals |
| US5364840A (en) * | 1989-12-05 | 1994-11-15 | Vical, Inc. | Synthetic calcitonin peptides |
| US5118667A (en) * | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
| JPH08507070A (ja) * | 1993-02-22 | 1996-07-30 | アルザ・コーポレーション | 活性物質の経口投与のための組成物 |
| US5866536A (en) * | 1995-03-31 | 1999-02-02 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
| US5723577A (en) | 1995-07-13 | 1998-03-03 | Biomeasure Inc. | Analogs of parathyroid hormone |
| US5955574A (en) * | 1995-07-13 | 1999-09-21 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. | Analogs of parathyroid hormone |
| ATE383169T1 (de) | 1997-02-07 | 2008-01-15 | Emisphere Tech Inc | Komponente und zusammensetzungen zur verabreichung von wirkstoffen |
| AR012448A1 (es) * | 1997-04-18 | 2000-10-18 | Ipsen Pharma Biotech | Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada |
| SE9702401D0 (sv) | 1997-06-19 | 1997-06-19 | Astra Ab | Pharmaceutical use |
| DE19915272A1 (de) * | 1999-04-03 | 2000-10-05 | Vetter & Co Apotheker | Spritze für medizinische Zwecke |
| NZ534409A (en) * | 1999-04-05 | 2006-03-31 | Emisphere Tech Inc | Disodium salts, monohydrates, and ethanol solvates for delivering active agents |
| WO2001032201A2 (en) | 1999-10-29 | 2001-05-10 | Eli Lilly And Company | A pharmaceutical composition having high cell membrane permeability |
| US7049283B2 (en) * | 2000-12-06 | 2006-05-23 | Novartis Ag | Pharmaceutical compositions for the oral delivery of pharmacologically active agents |
| JP5073153B2 (ja) | 2001-06-01 | 2012-11-14 | ノバルティス アーゲー | 副甲状腺ホルモンおよびカルシトニンの経口投与 |
| DE60233803D1 (de) * | 2001-08-17 | 2009-11-05 | Novartis Ag | 5-cnac zur oralen verabreichung von parathormonfragmenten |
| US7318925B2 (en) * | 2003-08-08 | 2008-01-15 | Amgen Fremont, Inc. | Methods of use for antibodies against parathyroid hormone |
-
2002
- 2002-05-31 JP JP2003501491A patent/JP5073153B2/ja not_active Expired - Fee Related
- 2002-05-31 AT AT02750997T patent/ATE356631T1/de active
- 2002-05-31 CA CA2446929A patent/CA2446929C/en not_active Expired - Fee Related
- 2002-05-31 MX MXPA03011027A patent/MXPA03011027A/es active IP Right Grant
- 2002-05-31 RU RU2003136733/15A patent/RU2300392C2/ru not_active IP Right Cessation
- 2002-05-31 PL PL364089A patent/PL211976B1/pl unknown
- 2002-05-31 KR KR1020097022621A patent/KR20090116836A/ko not_active Withdrawn
- 2002-05-31 CN CN200910258008A patent/CN101837120A/zh active Pending
- 2002-05-31 EP EP02750997A patent/EP1397156B1/en not_active Expired - Lifetime
- 2002-05-31 WO PCT/EP2002/006017 patent/WO2002098453A2/en not_active Ceased
- 2002-05-31 SK SK1475-2003A patent/SK287697B6/sk not_active IP Right Cessation
- 2002-05-31 IL IL15877702A patent/IL158777A0/xx unknown
- 2002-05-31 KR KR1020127010903A patent/KR101320817B1/ko not_active Expired - Fee Related
- 2002-05-31 NZ NZ529439A patent/NZ529439A/en not_active IP Right Cessation
- 2002-05-31 KR KR10-2003-7015524A patent/KR20040007617A/ko not_active Ceased
- 2002-05-31 DE DE60218842T patent/DE60218842T2/de not_active Expired - Lifetime
- 2002-05-31 AU AU2002344371A patent/AU2002344371B2/en not_active Ceased
- 2002-05-31 PT PT02750997T patent/PT1397156E/pt unknown
- 2002-05-31 ES ES02750997T patent/ES2282436T3/es not_active Expired - Lifetime
- 2002-05-31 CN CNA028111613A patent/CN1512892A/zh active Pending
- 2002-05-31 BR BRPI0209748A patent/BRPI0209748B1/pt not_active IP Right Cessation
- 2002-05-31 US US10/478,631 patent/US20040186050A1/en not_active Abandoned
- 2002-05-31 CZ CZ2003-3232A patent/CZ307145B6/cs not_active IP Right Cessation
- 2002-05-31 HU HU0400120A patent/HU229613B1/hu not_active IP Right Cessation
-
2003
- 2003-11-05 ZA ZA200308625A patent/ZA200308625B/xx unknown
- 2003-11-06 IL IL158777A patent/IL158777A/en not_active IP Right Cessation
- 2003-11-18 NO NO20035133A patent/NO330093B1/no not_active IP Right Cessation
- 2003-11-21 EC EC2003004858A patent/ECSP034858A/es unknown
- 2003-12-19 CO CO03111065A patent/CO5540323A2/es not_active Application Discontinuation
-
2006
- 2006-09-29 AU AU2006225157A patent/AU2006225157B2/en not_active Ceased
-
2008
- 2008-01-28 US US12/020,700 patent/US8153587B2/en not_active Expired - Fee Related
-
2010
- 2010-04-22 JP JP2010098631A patent/JP2010189423A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0400607A3 (en) | Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases | |
| JP2002523452A5 (enExample) | ||
| JP2003503454A5 (enExample) | ||
| RU2001128504A (ru) | Композиции для стимулирования роста | |
| JP2005503322A5 (enExample) | ||
| BRPI0411451A (pt) | formas de dosagens orais de memantina | |
| NZ544645A (en) | Use of calcitonin in osteoarthritis | |
| JP2006512324A5 (enExample) | ||
| DE602004016376D1 (de) | Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs | |
| CO5540323A2 (es) | Administracion oral de hormona paratiroides y calcitonina | |
| JP2003514025A5 (enExample) | ||
| JP2004525940A5 (enExample) | ||
| JP2002540148A5 (enExample) | ||
| IL167250A (en) | Chirale oxazole-arylpropionic acid derivatives, compositions comprising thereof and their use in the preparation of medicaments for the treatment of ppar alpha/ ppar gamma agonists-modulated diseases | |
| CA2496476A1 (en) | Therapeutic use | |
| RU2006131553A (ru) | Комбинация(а) ингибитора топоизомеразы днк и (б) ингибитора iap | |
| JP2003522147A5 (enExample) | ||
| JP2002326936A5 (enExample) | ||
| RU2002124141A (ru) | Применение миртазапина для лечения расстройств сна | |
| JP2021511352A5 (enExample) | ||
| JP2004503471A5 (enExample) | ||
| JP2004533434A5 (enExample) | ||
| CA2576926A1 (en) | Use of midostaurin for treating gastrointestinal stromal tumors | |
| TW200501967A (en) | Nemorubicin for use in the preparation of a medicament for liver disease | |
| RU2006108528A (ru) | Производные 2-алкилиден-19-нор-витамина d для лечения остеопении или мужского остеопороза |